This week, we bring you another interesting interview with Peter J. Werth, President and Chief Executive Officer of ChemWerth, a US-headquartered full-service generic active pharmaceutical ingredient (API) development and supply company providing current Good...
Peter J. Werth, President and Chief Executive Officer of ChemWerth, a US-headquartered full-service generic active pharmaceutical ingredient (API) development and supply company providing current Good Manufacturing Practices (cGMP) quality APIs to the regulated...
July 2017: ChemWerth Inc. and Hubei Enoray Biopharmaceutical Co., Ltd. (Enoray) are pleased to announce that Enoray has passed their second U.S. FDA inspection in July, 2017 with no 483 issued. The FDA inspection focused on Heparin API. ChemWerth has worked closely...
Opening remarks given by Ed Vanderbeck, COO, ChemWerth. 2 day cGMP training seminar in Shanghai, China. November 3-4th, 2016. ChemWerth has spent the last 35 years revising the answer to that question. Understand, it needs to be put into context in an industry that is...
Every year roughly ten million Americans receive the blood-thinning drug heparin, however in 2008 contaminated heparin resulted in about 350 adverse events and 150 deaths in the United States alone. Since then, heparin has attracted increasingly stringent attention...
Supplier of APIs for generic drug formulations expands its reach ChemWerth, Inc. has expanded distribution into Mexico and Central America, striking a deal with IDEOS Servicios y Especialidades Quìmicas S.A. de C.V. in Corregidora, Querétaro. The company will serve as...
